{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.68","upperLimit":"9.67","value":"5.45"},{"groupId":"OG001","lowerLimit":"1.96","upperLimit":"8.48","value":"4.44"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"165"},{"groupId":"OG001","value":"164"}],"units":"Participants"}],"title":"Month 3"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.34","upperLimit":"14.15","value":"9.13"},{"groupId":"OG001","lowerLimit":"3.28","upperLimit":"11.03","value":"6.43"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"152"},{"groupId":"OG001","value":"146"}],"units":"Participants"}],"title":"Month 6"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"10.26","upperLimit":"21.26","value":"15.30"},{"groupId":"OG001","lowerLimit":"9.94","upperLimit":"21.30","value":"15.12"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"143"},{"groupId":"OG001","value":"137"}],"units":"Participants"}],"title":"Month 12"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"10.78","upperLimit":"21.98","value":"15.93"},{"groupId":"OG001","lowerLimit":"11.06","upperLimit":"22.84","value":"16.48"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"128"},{"groupId":"OG001","value":"118"}],"units":"Participants"}],"title":"Month 18"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"12.37","upperLimit":"24.10","value":"17.83"},{"groupId":"OG001","lowerLimit":"13.36","upperLimit":"25.90","value":"19.22"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"121"},{"groupId":"OG001","value":"114"}],"units":"Participants"}],"title":"Month 24"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"12.37","upperLimit":"24.10","value":"17.83"},{"groupId":"OG001","lowerLimit":"13.94","upperLimit":"26.67","value":"19.22"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"117"},{"groupId":"OG001","value":"109"}],"units":"Participants"}],"title":"Month 30"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"12.37","upperLimit":"24.10","value":"17.83"},{"groupId":"OG001","lowerLimit":"15.73","upperLimit":"28.96","value":"22.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"114"},{"groupId":"OG001","value":"106"}],"units":"Participants"}],"title":"Month 36"}],"denoms":[{"counts":[{"groupId":"OG000","value":"165"},{"groupId":"OG001","value":"164"}],"units":"Participants"}],"description":"Defined as the cumulative incidence rate from competing risk analysis for NRM from the date of randomization to the date of death not preceded by underlying disease relapse/recurrence.","dispersionType":"95% Confidence Interval","groups":[{"description":"Ruxolitinib was administered orally twice per day at a dose of 10 milligrams (mg).","id":"OG000","title":"Ruxolitinib"},{"description":"Participants received best available therapies (BATs), including, but not limited to, extracorporeal photopheresis (ECP), low-dose methotrexate (MTX), mycophenolate mofetil (MMF), mTOR inhibitors (everolimus or sirolimus), infliximab, rituximab, pentostatin, imatinib, and ibrutinib based on the investigator's decision.","id":"OG001","title":"Best Available Therapy"}],"paramType":"NUMBER","populationDescription":"FAS. Only participants with available data were analyzed.","reportingStatus":"POSTED","timeFrame":"Months 3, 6, 12, 18, 24, 30, and 36","title":"Cumulative Incidence of Non-relapse Mortality (NRM)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}